As of Dec. 2, 10 oseltamivir products from five drugmakers were in short supply, according to the American Society of Health-System Pharmacists. The update is a minor improvement from a month ago when there were 12 products from six companies part of the dearth.
The back-ordered and allocated products include three from Amneal Pharmaceuticals, three from Camber Pharmaceuticals, two from Macleods Pharma, one from Zydus Lifesciences and one from Teva Pharmaceuticals.
